2026-06-29

Copper volume spike — 39.5× the 20-day average (32,837 vs 830 avg)

Silver volume spike — 612.9× the 20-day average (30,247 vs 49 avg)

Gold volume spike — 74.5× the 20-day average (103,093 vs 1,384 avg)

Platinum volume spike — 2161.3× the 20-day average (12,860 vs 5 avg)

CFTC COPPER speculators at extreme long: 52-week positioning extreme

Cotton bull 7.0% vs prior close ($71.66 → $76.66)

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

OSINT: Israel Signals Long-Term Military Presence in Lebanon

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

OSINT: Russia Faces Widespread Fuel Shortages Amid Growing War Discontent

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

OSINT: Europe bans gasoline for aviation, tightening fuel supply

CFTC COPPER speculators at extreme long: 52-week positioning extreme

CFTC BITCOIN speculators at extreme long: 52-week positioning extreme

CFTC NATURAL GAS speculators at extreme long: 52-week positioning extreme

OSINT: Trump Announces Plan for Public Golf Course in Washington D.C.

30Y Treasury Bond volume spike — 2.2× the 20-day average (293,621 vs 130,792 avg)

Sugar No. 11 bull 5.9% vs prior close ($13.98 → $14.80)

SOL open interest +235.1% — OI surge

ETH open interest +207.5% — OI surge

BTC open interest +77.3% — OI surge

BTC open interest -43.9% — OI collapse

SOL open interest +32.2% — OI surge

ETH open interest -67.9% — OI collapse

BTC open interest -69.6% — OI collapse

ETH open interest +208.3% — OI surge

SOL open interest -61.4% — OI collapse

SOL open interest -24.3% — OI collapse

BTC open interest -45.2% — OI collapse

ETH open interest +207.1% — OI surge

OSINT: SVB reports $67B crypto-backed lending in Q1 2026, rebound from crises

SOL DEX volume/liquidity ratio elevated (1.45x): on-chain trade volume 1.45x liquidity

OSINT: Top 10 DeFi protocols generate >80% of holder revenue in past week

OSINT: AI-linked sectors see sharp job losses, avg 11k per month

OSINT: Defense Sec. Hegseth appoints Marc Andreessen to Pentagon Defense Policy Board

ETH RSI 27.8 — oversold (crossed below 30)

OSINT: Solana Launches FlashTrade V2 Perps with 50ms Execution and Gasless Trading

ETH DEX volume/liquidity ratio elevated (0.50x): on-chain trade volume 0.50x liquidity

SOL DEX volume/liquidity ratio elevated (1.55x): on-chain trade volume 1.55x liquidity

Phase 3 trial terminated early — BRISTOL A Phase 4 Study to Assess the Effects of Aripiprazole Versus Other Atypical Anti

Phase 3 trial terminated early — BIOGEN Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2

Phase 3 trial terminated early — BIOGEN An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)

Phase 3 trial terminated early — BIOGEN A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Ho

Phase 3 trial terminated early — AMGEN TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel

Phase 3 trial terminated early — Medtronic Radial Reload Laparoscopic LAR Case Series

Phase 3 trial terminated early — Merck A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant

Phase 3 trial terminated early — Merck Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density L

Phase 3 trial terminated early — Merck An Open-label Study to Identify Molecular Markers of Steroid Resistance

Phase 3 trial terminated early — Merck Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized

Phase 3 trial terminated early — PFIZER Neuromuscular Changes In Small For Gestational Age Children During Somatropin Th

Phase 3 trial terminated early — PFIZER A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease P

Phase 3 trial terminated early — PFIZER Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment O

Phase 3 trial terminated early — PFIZER Efficacy and Safety Study of Celecoxib and Pregabalin Compared With Celecoxib Mo

Phase 3 trial terminated early — ABBOTT Study of Blood Concentrations and Physiologic Effects of Levosimendan Given Duri

Phase 3 trial terminated early — ABBOTT Effect of Enteral Nutrition Support for Critically Ill Patients

Phase 3 trial terminated early — GILEAD Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitab

Arcosa, Inc. search volume spiked +100 pts — unusual interest

OSINT: SVB reports $67B crypto-backed lending in Q1 2026, rebound from crises

OSINT: Ukraine equips M113 APCs with ‘hamster ball’ cage armor to counter drones

OSINT: Assassination Attempt on Ukrainian Oligarch in Monaco Raises Security Concerns

SOUTHERN CO search volume spiked +27 pts — unusual interest

OSINT: AI-linked sectors see sharp job losses, avg 11k per month

BLACK HILLS CORP /SD/ search volume spiked +100 pts — unusual interest

OSINT: Defense Sec. Hegseth appoints Marc Andreessen to Pentagon Defense Policy Board

Parker-Hannifin Corp search volume spiked +100 pts — unusual interest

Birkenstock Holding plc search volume spiked +100 pts — unusual interest

OSINT: Solana Launches FlashTrade V2 Perps with 50ms Execution and Gasless Trading

Arcosa, Inc. search volume spiked +100 pts — unusual interest

SOUTHERN CO search volume spiked +27 pts — unusual interest

BLACK HILLS CORP /SD/ search volume spiked +100 pts — unusual interest

Parker-Hannifin Corp search volume spiked +100 pts — unusual interest

Q3-2025: Beat consensus by 5.2% — EPS $1.58 vs $1.5012 estimate

Q1-2026: Beat consensus by 7.6% — EPS $1.5 vs $1.3943 estimate

Q1-2026: Beat consensus by 207.8% — EPS $0.011 vs $-0.0102 estimate

Q4-2026: Missed consensus by 129.4% — EPS $-0.003 vs $0.0102 estimate

Q1-2026: Missed consensus by 595.8% — EPS $-0.78 vs $-0.1121 estimate

Q4-2025: Missed consensus by 25.8% — EPS $-0.29 vs $-0.2305 estimate

Q1-2020: Missed consensus by 88.1% — EPS $0.2 vs $1.6766 estimate

Q3-2024: Beat consensus by 201.9% — EPS $3552.91 vs $1176.8008 estimate

Q4-2024: Missed consensus by 296.3% — EPS $-791.835 vs $403.2991 estimate

Q1-2026: Beat consensus by 12.0% — EPS $0.38 vs $0.3392 estimate

Q4-2025: Beat consensus by 5.8% — EPS $0.31 vs $0.2929 estimate

Q2-2025: Beat consensus by 7.9% — EPS $0.26 vs $0.241 estimate

Q1-2025: Missed consensus by 25.7% — EPS $0.25 vs $0.3366 estimate

Q3-2025: Beat consensus by 10.9% — EPS $0.43 vs $0.3876 estimate

Q2-2025: Beat consensus by 10.4% — EPS $1.302 vs $1.1797 estimate

Q1-2026: Beat consensus by 24.6% — EPS $1.15 vs $0.9229 estimate

Q3-2025: Missed consensus by 9.6% — EPS $0.93 vs $1.0288 estimate

Q3-2021: Beat consensus by 253.0% — EPS $16 vs $4.532 estimate

Q4-2021: Missed consensus by 23.7% — EPS $13.2 vs $17.304 estimate

Q2-2014: Missed consensus by 30.7% — EPS $-0.4 vs $-0.306 estimate

Q1-2014: Missed consensus by 51.0% — EPS $0.1 vs $0.204 estimate

Q4-2023: Missed consensus by 197.6% — EPS $-168.35 vs $-56.56 estimate

Q3-2024: Missed consensus by 61.5% — EPS $-21.7 vs $-13.433 estimate

Q1-2024: Missed consensus by 47.1% — EPS $-18.2 vs $-12.3725 estimate

Q1-2027: Beat consensus by 5.6% — EPS $0.14 vs $0.1326 estimate

Q2-2025: Beat consensus by 18.1% — EPS $0.66 vs $0.559 estimate

Q1-2026: Beat consensus by 43.1% — EPS $0.26 vs $0.1817 estimate

Q2-2025: Beat consensus by 13.7% — EPS $0.67 vs $0.5893 estimate

Q4-2025: Missed consensus by 7.5% — EPS $0.61 vs $0.6592 estimate

Q3-2025: Beat consensus by 15.8% — EPS $0.61 vs $0.5266 estimate

Q1-2026: Beat consensus by 11.7% — EPS $0.3 vs $0.2686 estimate

Q2-2012: Beat consensus by 126.3% — EPS $20 vs $-76.1532 estimate

Q1-2012: Missed consensus by 134.2% — EPS $-180 vs $-76.8468 estimate

Q4-2012: Missed consensus by 14.2% — EPS $140 vs $163.2 estimate

Q3-2012: Beat consensus by 586.3% — EPS $140 vs $20.4 estimate

Q4-2025: Missed consensus by 138.1% — EPS $-0.17 vs $-0.0714 estimate

Q1-2026: Beat consensus by 34.6% — EPS $-0.04 vs $-0.0612 estimate

Q2-2026: Missed consensus by 56.9% — EPS $-0.08 vs $-0.051 estimate

Q3-2025: Missed consensus by 929.4% — EPS $-0.21 vs $-0.0204 estimate

Q2-2025: Missed consensus by 7.6% — EPS $0.91 vs $0.9847 estimate

Q1-2026: Beat consensus by 9.5% — EPS $1.64 vs $1.4975 estimate

Q1-2026: Beat consensus by 66.0% — EPS $42.52 vs $25.6166 estimate

Q3-2025: Missed consensus by 161.9% — EPS $-9.96 vs $16.1024 estimate

Q2-2025: Missed consensus by 14.4% — EPS $23.14 vs $27.0246 estimate

Q4-2025: Missed consensus by 354.1% — EPS $-28.11406 vs $11.062 estimate

Q1-2026: Beat consensus by 5.2% — EPS $0.22 vs $0.2091 estimate

Q4-2025: Beat consensus by 42.0% — EPS $0.25 vs $0.1761 estimate

Q3-2026: Beat consensus by 30.3% — EPS $524.42805 vs $402.4668 estimate

Q1-2026: Missed consensus by 113.2% — EPS $-104.41 vs $-48.9668 estimate

Q2-2026: Beat consensus by 183.1% — EPS $437.38079 vs $154.5037 estimate

Q4-2026: Beat consensus by 25.8% — EPS $737.77 vs $586.3999 estimate

Q3-2025: Missed consensus by 19.9% — EPS $0.54 vs $0.6738 estimate

Q1-2026: Beat consensus by 24.4% — EPS $0.85 vs $0.6831 estimate

Q2-2025: Missed consensus by 11.0% — EPS $0.62 vs $0.6963 estimate

Q3-2025: Beat consensus by 10.0% — EPS $1.37 vs $1.2452 estimate

Q2-2025: Beat consensus by 7.9% — EPS $1.26 vs $1.1675 estimate

Q3-2019: Missed consensus by 36.3% — EPS $0.45 vs $0.7066 estimate

Q4-2019: Missed consensus by 11.1% — EPS $0.3 vs $0.3376 estimate

Q2-2019: Beat consensus by 35.1% — EPS $0.93 vs $0.6882 estimate

Q1-2020: Missed consensus by 246.7% — EPS $-0.42 vs $0.2863 estimate

Q4-2025: Beat consensus by 98.8% — EPS $-1.8 vs $-149.94 estimate

Q1-2026: Missed consensus by 322.0% — EPS $-361.6 vs $-85.68 estimate

Q2-2025: Missed consensus by 114.9% — EPS $-4083 vs $-1900.26 estimate

Q3-2025: Missed consensus by 42.4% — EPS $-318 vs $-223.38 estimate

Q3-2023: Missed consensus by 191.7% — EPS $-2.38 vs $-0.816 estimate

Q4-2022: Missed consensus by 83.8% — EPS $-3 vs $-1.632 estimate

Q1-2023: Beat consensus by 47.2% — EPS $-1.4 vs $-2.652 estimate

Q3-2025: Missed consensus by 96.1% — EPS $-0.02 vs $-0.0102 estimate

Q3-2025: Beat consensus by 296.1% — EPS $0.01 vs $-0.0051 estimate

Q2-2025: Beat consensus by 296.1% — EPS $0.02 vs $-0.0102 estimate

Q1-2026: Missed consensus by 17.6% — EPS $-0.02 vs $-0.017 estimate

Q4-2025: Beat consensus by 100.0% — EPS $0 vs $-0.0051 estimate

Q1-2026: Missed consensus by 12.5% — EPS $-0.52 vs $-0.4624 estimate

Q2-2025: Missed consensus by 40.1% — EPS $-0.55 vs $-0.3927 estimate

Q4-2025: Missed consensus by 17.6% — EPS $-0.58 vs $-0.493 estimate

Q3-2025: Beat consensus by 5.8% — EPS $-0.49 vs $-0.5202 estimate

Q2-2025: Beat consensus by 18.3% — EPS $-0.1 vs $-0.1224 estimate

Q3-2025: Beat consensus by 11.8% — EPS $-0.09 vs $-0.102 estimate

Q1-2026: Beat consensus by 11.8% — EPS $-0.09 vs $-0.102 estimate

Q4-2025: Missed consensus by 30.7% — EPS $-0.12 vs $-0.0918 estimate

Q2-2025: Missed consensus by 9.3% — EPS $-0.92 vs $-0.8415 estimate

Q1-2026: Beat consensus by 2102.1% — EPS $1.94 vs $-0.0969 estimate

Q3-2025: Missed consensus by 8.0% — EPS $-1.08 vs $-0.9996 estimate

Q4-2025: Beat consensus by 47.7% — EPS $-0.58 vs $-1.1098 estimate

Q1-2026: Beat consensus by 7.0% — EPS $-0.12 vs $-0.129 estimate

Q4-2025: Missed consensus by 128.8% — EPS $-0.07 vs $-0.0306 estimate

Q3-2025: Missed consensus by 173.5% — EPS $-0.03 vs $0.0408 estimate

Q1-2026: Missed consensus by 107.1% — EPS $-0.01 vs $0.1401 estimate

Q2-2025: Beat consensus by 345.5% — EPS $0.45 vs $0.101 estimate

Q3-2025: Missed consensus by 18.8% — EPS $0.1 vs $0.1232 estimate

Q4-2025: Missed consensus by 95.5% — EPS $0.01 vs $0.2222 estimate

Q1-2026: Beat consensus by 15.2% — EPS $0.59 vs $0.5123 estimate

Q3-2025: Beat consensus by 5.8% — EPS $0.67 vs $0.6331 estimate

Q2-2025: Beat consensus by 9.4% — EPS $0.62 vs $0.5669 estimate

Q4-2025: Beat consensus by 76.9% — EPS $0.15 vs $0.0848 estimate

Q3-2025: Beat consensus by 15.5% — EPS $0.14 vs $0.1212 estimate

Q1-2026: Missed consensus by 11.4% — EPS $0.11 vs $0.1241 estimate

Q3-2025: Beat consensus by 98.4% — EPS $1.72 vs $0.867 estimate

Q1-2026: Missed consensus by 56.5% — EPS $0.44 vs $1.0124 estimate

Q4-2025: Missed consensus by 31.7% — EPS $0.61 vs $0.8925 estimate

Q2-2025: Beat consensus by 108.2% — EPS $1.55 vs $0.7446 estimate

Q4-2025: Beat consensus by 240.3% — EPS $0.18 vs $0.0529 estimate

Q2-2025: Missed consensus by 35.6% — EPS $0.03 vs $0.0466 estimate

Q1-2026: Beat consensus by 180.2% — EPS $0.13 vs $0.0464 estimate

Q3-2025: Missed consensus by 38.9% — EPS $0.03 vs $0.0491 estimate

Q3-2026: Beat consensus by 9.2% — EPS $-0.45 vs $-0.4957 estimate

Q2-2026: Missed consensus by 11.2% — EPS $-0.54 vs $-0.4855 estimate

Q4-2026: Missed consensus by 7.7% — EPS $-0.37 vs $-0.3434 estimate

Q1-2026: Missed consensus by 27.2% — EPS $0.023 vs $0.0316 estimate

Q4-2025: Beat consensus by 5.3% — EPS $0.054 vs $0.0513 estimate

Q3-2025: Beat consensus by 18.9% — EPS $0.034 vs $0.0286 estimate

Q2-2025: Missed consensus by 37.3% — EPS $0.016 vs $0.0255 estimate

Q1-2024: Beat consensus by 15.2% — EPS $-68.4 vs $-80.6208 estimate

Q1-2025: Missed consensus by 71.6% — EPS $-6.65 vs $-3.876 estimate

Q2-2024: Missed consensus by 107.6% — EPS $-105.83 vs $-50.9694 estimate

Q3-2024: Missed consensus by 9.5% — EPS $-38.19 vs $-34.884 estimate

Q4-2025: Missed consensus by 48.3% — EPS $0.03 vs $0.058 estimate

OSINT: USAF Conducts Coronet East Exercise with KC-135 Tankers and A-10Cs

OSINT: Ukraine equips M113 APCs with ‘hamster ball’ cage armor to counter drones

OSINT: Assassination Attempt on Ukrainian Oligarch in Monaco Raises Security Concerns

OSINT: Defense Sec. Hegseth appoints Marc Andreessen to Pentagon Defense Policy Board

OSINT: Paraguay and Germany deadlocked 1-1, match heads to extra time

OSINT: Assassination Attempt on Ukrainian Oligarch in Monaco Raises Security Concerns

OSINT: AI-linked sectors see sharp job losses, avg 11k per month